Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Sposto

Showing results (111-120 of 180) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|July 31, 2007
Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group reportRodney R Miles, Mitchell S Cairo, Prakash Satwani, et al.
Journal of Neuro-Oncology|February 11, 2018
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumorsNathan J Robison, Kee Kiat Yeo, Adrian P Berliner, et al.
Experimental Cell Research|April 8, 2015
Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentrationMichael A Sheard, Matthew V Ghent, Daniel J Cabral, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyRichard H Ko, Lingyun Ji, Phillip Barnette, et al.
Journal of Pediatric Hematology/Oncology|November 27, 2013
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumElizabeth A Raetz, Debra Morrison, Eleny Romanos-Sirakis, et al.
Pediatric Blood & Cancer|July 21, 2016
Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemiaWeili Sun, Etan Orgel, Jemily Malvar, et al.
Molecular Cancer Research : MCR|December 11, 2020
N-Acetyl-L-cysteine Promotes <i>Ex Vivo</i> Growth and Expansion of Single Circulating Tumor Cells by Mitigating Cellular Stress ResponsesTeng Teng, Mohamed Kamal, Oihana Iriondo, et al.
Pediatric Blood & Cancer|June 18, 2009
Premature carotid artery disease in pediatric cancer survivors treated with neck irradiationKathleen A Meeske, Stuart E Siegel, Vicente Gilsanz, et al.
BMC Research Notes|April 24, 2014
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I studyMin H Kang, Judith G Villablanca, Julia L Glade Bender, et al.
Haematologica|April 13, 2019
Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controlsPayal Shah, Maha Khaleel, Wanwara Thuptimdang, et al.
Pageof 18

Showing results (111-120 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|July 31, 2007
Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group reportRodney R Miles, Mitchell S Cairo, Prakash Satwani, et al.
Journal of Neuro-Oncology|February 11, 2018
Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumorsNathan J Robison, Kee Kiat Yeo, Adrian P Berliner, et al.
Experimental Cell Research|April 8, 2015
Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentrationMichael A Sheard, Matthew V Ghent, Daniel J Cabral, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2009
Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyRichard H Ko, Lingyun Ji, Phillip Barnette, et al.
Journal of Pediatric Hematology/Oncology|November 27, 2013
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortiumElizabeth A Raetz, Debra Morrison, Eleny Romanos-Sirakis, et al.
Pediatric Blood & Cancer|July 21, 2016
Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemiaWeili Sun, Etan Orgel, Jemily Malvar, et al.
Molecular Cancer Research : MCR|December 11, 2020
N-Acetyl-L-cysteine Promotes <i>Ex Vivo</i> Growth and Expansion of Single Circulating Tumor Cells by Mitigating Cellular Stress ResponsesTeng Teng, Mohamed Kamal, Oihana Iriondo, et al.
Pediatric Blood & Cancer|June 18, 2009
Premature carotid artery disease in pediatric cancer survivors treated with neck irradiationKathleen A Meeske, Stuart E Siegel, Vicente Gilsanz, et al.
BMC Research Notes|April 24, 2014
Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I studyMin H Kang, Judith G Villablanca, Julia L Glade Bender, et al.
Haematologica|April 13, 2019
Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controlsPayal Shah, Maha Khaleel, Wanwara Thuptimdang, et al.
Pageof 18